P-305 DREAMM-20: a Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma (MM) when Used As Monotherapy and in Combination Treatments

S206of 14.6 months (m) (interquartile range, 3,7-54,1), no differences in the progression-free survival (PFS) were observed between the CAR-T and the BiAbs groups (14.1 vs. 12,1 m; P=0.110), but patients receiving CAR-T achieved longer overall survival (OS) (43.0 vs. 18.2 m, hazard ratio 2.3 [95% CI, 1.1-5.2];P=0.050).Thirty-two patients (12 in the CAR-T and 20 in the BiAbs group) were rescued after progression.Overall, these rescue therapies were very heterogeneous, but 66.7% of the CAR-T group and 25% of the BiAbs group were treated with BiAbs in the subsequent treatment.Patients treated with BiAbs at relapsed showed a trend toward better response.Patients in the CAR-T group who were treated with BiAbs (with a different target than the BCMA) presented the longest PFS 2 (29.1 m), significantly more prolonged than patients in this group rescued with other schemes, (7,9 m, P< 0.001), as well as patients of the BiAbs group regardless of the treatment used at relapse (BiAbs: 7,3 m, P< 0.001; and other therapies: 8.4 m, P=0.002).Conclusions: The present study showed that CAR-T and BiAbs are effective treatment in TCR MM patients.In this scenario, CAR-T resulted in better responses, but no differences were observed in PFS compared to BiAbs.However, patients of the CAR-T group presented superior OS showing the importance of treatment sequence and how BiAbs could be useful after CAR-T to improve survival in TCR patients.The identification of sequence approach as well as the development of novel drugs represent the new unmet medical need in the relapse of patients TCR after the new immunotherapy.